CellCentric Strengthens Leadership Team
CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments of Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Both have stellar experience and track records in oncology research and development.
CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications. The first-in-class small molecule p300/CBP inhibitor that has the potential to treat a number of established but difficult to treat oncogenes.
Kris Frese is an experienced cancer biologist who specialises in models of cancer and biomarker analysis. Kris most recently served as an Associate Scientist at Cancer Research UK where he co-led the Cancer Biomarker Centre Preclinical Pharmacology Team.
Andrew Hughes, who has acted as Chief Development Adviser to the company to date, has more than 25 years’ experience of oncology clinical development in biotechnology and pharmaceutical companies. He previously led over 50 oncology research and development programmes of novel drug candidates at AstraZeneca Pharmaceuticals. Andrew is also Honorary Professor of Experimental Cancer Medicine at The University of Manchester and has a strong track record of executing clinical development programmes, resulting in successful product registrations.
Kris Frese, Director of Cancer Biology of CellCentric said: “I am excited to join CellCentric at this stage of development. I have been impressed by the comprehensive research and compelling early clinical data in the treatment of different indications of cancer. I look forward to working closely with the team to maximise the potential of inobrodib to deliver improved treatments for people with cancer.”
Andrew Hughes, Chief Development Adviser and Board Member of CellCentric, commented: “Inobrodib is a highly-differentiated, first-in-class compound with a novel mechanism of action. It can treat different indications of cancer, including both solid tumours and haematological cancers. My experience in executing expanding clinical development programmes, leading to successful product registrations, can help to further progress inobrodib’s development.”
Will West, Chief Executive Officer of CellCentric added: “CellCentric is entering an exciting stage as it begins to transition to Phase II clinical trials of inobrodib. Our vision is to make a real difference to the lives of people with cancer which we can only deliver with an excellent team of highly experienced, motivated people. Both Kris and Andrew have a wealth of knowledge in oncology and clinical development that will be invaluable to accelerate the further development of inobrodib in multiple specific clinical settings.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more